Zobrazeno 1 - 10
of 392
pro vyhledávání: '"biosimilarity"'
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 23, Iss 4, Pp 480-498 (2023)
Scientific relevance. The clinical effects and the expiration of patents for original (reference) biotechnological medicines based on monoclonal antibodies (mAbs) stimulated the development of biosimilar mAbs. The quality profile of a biosimilar mAb
Externí odkaz:
https://doaj.org/article/a238d050a1dd47959698a4419c4b9c0f
Autor:
Niazi SK
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 281-294 (2023)
Sarfaraz K Niazi College of Pharmacy, University of Illinois, Chicago, IL, 60612, USACorrespondence: Sarfaraz K Niazi, Tel +1-312-297-0000, Email niazi@niazi.comAbstract: Almost two decades since biosimilars arrived, we still await their broader adop
Externí odkaz:
https://doaj.org/article/12c05f47effb4c97a92ee6154cd1ae1e
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 321 (2024)
By definition, biosimilar medicinal products are biological medicinal products that are similar to other biological medicinal products that are already on the market—the reference medicinal products. Access to biosimilar medicines is a current real
Externí odkaz:
https://doaj.org/article/d76631678d5849d7bea1a6fb12b1b66f
Autor:
Igor Makarenko, Artem Dorotenko, Sergey Noskov, Veniamin Banko, Valeria Saparova, Alexandr Khokhlov, Evgeniia Zoreeva, Andrey Nedorubov, Bella Zinnatulina, Maria Gefen, Roman Drai
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 5, Pp n/a-n/a (2023)
Abstract Aims The pharmacodynamic (PD) similarity between GP40141, a proposed romiplostim biosimilar, and reference romiplostim was evaluated. Pharmacokinetics and safety were also assessed. Methods In this phase 1, randomized, double‐blind, single
Externí odkaz:
https://doaj.org/article/e6fff10272504c27af32e229a159a688
Autor:
Niazi S
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 2803-2815 (2022)
Sarfaraz Niazi Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, IL, USACorrespondence: Sarfaraz Niazi, Email niazi@niazi.comAbstract: After 18 years and the administration of billions of doses, there is lit
Externí odkaz:
https://doaj.org/article/23822d39a7f14079bc13f6b739f5fd8e
Autor:
Hua Sang, Jiali Liu, Fang Zhou, Xiaofang Zhang, Jingwei Zhang, Yazhong Liu, Guangji Wang, Hui Ye
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 4020-4031 (2021)
Events including antibody‒antigen affinity, internalization, trafficking and lysosomal proteolysis combinatorially determine the efficiency of antibody–drug conjugate (ADC) catabolism and hence the toxicity. Nevertheless, an approach that conveni
Externí odkaz:
https://doaj.org/article/bb954aa9042641a18b9144a769086c4c
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Externí odkaz:
https://doaj.org/article/5fe0d1af7759426b87c0785f4dd93616
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Insulin glargine is a long-acting insulin analog, which plays an important role in the treatment of diabetes mellitus. Biosimilar products of insulin glargine can provide patients with additional safe, high-quality, and potentially cost-effective opt
Externí odkaz:
https://doaj.org/article/43d95216397b41c49e2a2765a4fec453
Publikováno v:
Molecules, Vol 28, Iss 8, p 3304 (2023)
Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety. Due to the heterogenic and complex nature of protein glycosylation, co
Externí odkaz:
https://doaj.org/article/106fca81a53a4b10abca114d6daaf4d1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.